Autoimmune Diseases  >>  itacitinib (INCB039110)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
itacitinib (INCB039110) / Incyte
NCT01626573: A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

Completed
2
106
US
Itacitinib, INCB039110, Itacitinib Placebo
Incyte Corporation
Rheumatoid Arthritis
07/13
10/13

Download Options